ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 181

Identification of Disease-Susceptible Lncrna Contributed to Abnormal Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus

Nan Shen1,2, Yuanjia Tang3, Zhixin Xue3 and Chaojie Cui4, 1Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, 2The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH, 3Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: interferons and polymorphism, RNA, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Dysregulation or dysfunction of some key moleculars in signaling pathway is involved in disease pathogenesis. Long non-coding RNA (lncRNA), as a regulator of gene expression, plays great role in signaling pathway. The majority of susceptible single nucleotide polymorphisms (SNPs) of systemic lupus erythematosus (SLE) identified in GWAS studies are located in noncoding regions of the human genome. We hypothesized that disease-related functional SNP linked to lncRNA may affect expression or function of lncRNA and involve in key signaling pathway of SLE.

Methods:

Deep sequencing of human renal samples to screen differential expression of lncRNAs between LN patients and healthy donors and mining GWAS data were applied to get candidate lncRNAs. RNA-FISH was used to identify subcellular location of lncRNA. Reporter gene assay was applied to ascertain effect of disease-related SNP on lncMKLN1 transcription. Stimulation in human renal mesangial cells (HRMC) by all kinds of TLR ligands, IFNs, and TNFα, and transfection in HRMC cells by antisense oligonucleotides (ASOs), and quantitative real-time polymerase chain reaction (RT-qPCR) were used to analyze the relative genes expression. LncMKLN1 transcription was activated or inhibited through CRISPR-dCas9 system in Hela cell line. RNA-seq was executed to examine the gene expression profile after changing lncMKLN1 expression, and western blot was applied to determine the key signaling molecules of IFN pathway.

Results:

LncMKLN1, dominantly located in nucleus, was up-regulated in lupus patients compared to healthy donors, and could be induced by IFNα and TLR ligands in HRMC. GWAS data showed that there were two lupus-related SNPs located within proximal region of lncMKLN1 promoter. Promoter constructs containing susceptible allele have higher activity of transcription compared to another allele. Silencing lncMKLN1 significantly reduced the expression of a group of interferon-inducible genes, including IFIT3, OAS1, CXCL10, etc. We used lose-of-function and gain-of-function strategy through CRSIPR system to confirm that lncMKLN1 positively regulated type I interferon pathway. Furthermore, it was identified the involvement of lncMKLN1 in interferon signaling pathway was through regulating the expression of STAT1, IRF9 and phosphorylation of IRF9 and STAT1 although its mechanism is also needed to investigate.

Conclusion:

Functional susceptible SNP enhances lncMKLN1 expression, resulting in abnormal activation of interferon pathway of SLE.


Disclosure: N. Shen, None; Y. Tang, None; Z. Xue, None; C. Cui, None.

To cite this abstract in AMA style:

Shen N, Tang Y, Xue Z, Cui C. Identification of Disease-Susceptible Lncrna Contributed to Abnormal Activation of Type I Interferon Pathway in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identification-of-disease-susceptible-lncrna-contributed-to-abnormal-activation-of-type-i-interferon-pathway-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-disease-susceptible-lncrna-contributed-to-abnormal-activation-of-type-i-interferon-pathway-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology